Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ketan Patel

Plastic Surgery Tarzana, CA Medical Doctor

NPI 1033344817 CMS profile 137877

5411 Etiwanda Ave Ste 200, Tarzana, CA 91356

Open in the dashboard

General payments

$109,258

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ketan Patel of Tarzana, CA is reported in the CMS Open Payments database as having received $109,258 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,333 62
2024 General $22,592 80
2023 General $19,291 60
2022 General $37,616 48
2021 General $1,556 20
2020 General $177 2
2019 General $7,693 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ketan Patel
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Ketan Patel were reported at $20,333. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Ketan Patel Plastic Surgery median Middle half National median
2019 $7,693 $371 $122–$1,483 $163
2020 $177 $158 $52–$438 $114
2021 $1,556 $249 $87–$752 $132
2022 $37,616 $274 $102–$793 $149
2023 $19,291 $299 $113–$891 $160
2024 $22,592 $361 $124–$1,062 $164
2025 $20,333 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $87,966 72 payments
  2. TELA Bio, Inc. $3,923 35 payments
  3. PolyNovo North America LLC $3,739 36 payments
  4. Sientra, Inc. $2,045 21 payments
  5. AbbVie, Inc. $2,010 19 payments
  6. Integra LifeSciences Corporation $1,774 14 payments
  7. Motiva USA, LLC $1,291 14 payments
  8. AxoGen $999 11 payments
  9. Davol Inc. $903 7 payments
  10. Allergan Inc. $731 15 payments
  11. Other $3,877 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $79,100 24 payments
  2. Food and Beverage $22,371 231 payments
  3. Travel and Lodging $7,324 29 payments
  4. Long term medical supply or device loan $462 3 payments
Products named General payments · program years 2019–2025
  1. SPY-PHI SYSTEM $56,249 47 payments
  2. 1688 $21,791 8 payments
  3. 1788 $6,080 5 payments
  4. AIM LAPARASCOPES $4,500 1 payment
  5. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $2,314 20 payments
  6. NEW PRODUCT DEVELOPMENT $2,313 3 payments
  7. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $2,045 21 payments
  8. NOVOSORB BTM $1,899 19 payments
  9. NATRELLE SALINE-FILLED BREAST IMPLANTS $1,672 16 payments
  10. OviTex 2S $1,608 15 payments
  11. Other $16,678 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$102,035

Medicare's payments for the services billed

Medicare patients

144

Average age 70

Services billed

410

121 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 73%
High blood pressure 69%
Arthritis 57%
Osteoporosis 31%
Ischemic heart disease 27%
Diabetes 26%
Depression 24%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record